Healius Ltd (ASX: HLS) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Healius Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $1.02 billion
P/E Ratio 55.56
Dividend Yield 0.00%
Shares Outstanding 726.13 million
Earnings per share -0.964
Dividend per share 0.12
Year To Date Return -14.37%
Earnings Yield 1.80%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Healius Ltd (ASX: HLS)
    Latest News

    a woman
    Healthcare Shares

    Healius share price on watch after trading update

    The Healius Ltd (ASX: HLS) share price is on watch as the Aussie healthcare company provided a trading update at…

    Read more »

    a woman
    Share Market News

    Why Healius shares are climbing on its profit report

    Healius Ltd (ASX:HLS) delivered profit and revenue growth.

    Read more »

    a woman
    Share Gainers

    Why Baby Bunting, Cochlear, Healius, & Star Entertainment raced higher today

    The Baby Bunting Group Ltd (ASX:BBN) share price and the Cochlear Limited (ASX:COH) share price are two of four ending…

    Read more »

    a woman
    Share Market News

    Healius flags underlying profit to hit "low end" of guidance, looks for new CFO

    Healius meets the bottom end of analysts' expectations.

    Read more »

    a woman
    Mergers & Acquisitions

    2 lasting impacts from the latest multi-billion ASX takeover

    The sale of Healthscope Ltd (ASX: HSO) is one of the largest deals involving private equity and it has two…

    Read more »

    a woman
    Record Lows

    Is it time to buy the record low Virtus Health share price?

    Expectations going into Virtus Health Ltd’s (ASX: VRT) results were already low but the profit announcement send its shares crashing…

    Read more »

    a woman
    Share Gainers

    Healius shares gain even as it downgrades guidance and cuts divided

    The Healius Ltd (ASX: HLS) share price is bucking the weak market open this morning as the medical facilities operator…

    Read more »

    a woman
    Share Gainers

    These were the best performing shares on the ASX 200 in January

    Fortescue Metals Group Limited (ASX:FMG) and Afterpay Touch Group Ltd (ASX:APT) shares were amongst the best performers on the ASX…

    Read more »

    a woman
    Share Gainers

    Is it too late to buy Beach Energy and two other market-beating ASX shares?

    The Beach Energy Ltd (ASX:BPT) share price is one of three storming higher in 2019. Is it too late to…

    Read more »

    a woman
    Share Market News

    ALL ORDINARIES finishes lower Friday: 8 shares you missed

    The S&P/ASX 200 (Index:^AXJO)(ASX:XJO) and ALL ORDINARIES (Index:^AXAO) (ASX:XAO) finished lower on Friday.

    Read more »

    a woman
    Share Market News

    ASX 200 lunch time report: BHP, CBA, & Costa lower

    BHP Group Ltd (ASX:BHP), Costa Group Holdings Ltd (ASX:CGC), and Orocobre Limited (ASX:ORE) shares are making waves on the ASX…

    Read more »

    a woman
    Share Market News

    5 things to watch on the ASX 200 on Thursday

    A2 Milk Company Ltd (ASX:A2M), BHP Group Ltd (ASX:BHP), and Healius Ltd (ASX:HLS) shares will be on watch on the…

    Read more »

    Frequently Asked Questions

    Yes, Healius has historically paid two fully franked shareholder dividends a year.

    Healius has generally paid its shareholder dividends in March/April and September/October.

    Healius Ltd listed on the ASX on 3 July 1998.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    07 Sep 2022 $0.0600 100.00% Final 21 Sep 2022
    24 Mar 2022 $0.1000 100.00% Interim 05 Apr 2022
    13 Sep 2021 $0.0675 100.00% Final 08 Oct 2021
    25 Mar 2021 $0.0650 100.00% Interim 15 Apr 2021
    26 Mar 2020 $0.0260 100.00% Interim 15 Oct 2020
    29 Aug 2019 $0.0340 100.00% Final 27 Sep 2019
    15 Mar 2019 $0.0380 100.00% Interim 26 Mar 2019
    27 Aug 2018 $0.0550 100.00% Final 17 Sep 2018
    16 Mar 2018 $0.0510 100.00% Interim 27 Mar 2018
    31 Aug 2017 $0.0000 100.00% Final 18 Sep 2017
    17 Mar 2017 $0.0480 100.00% Interim 28 Mar 2017
    01 Sep 2016 $0.0640 100.00% Final 19 Sep 2016
    18 Mar 2016 $0.0560 50.00% Interim 29 Mar 2016
    26 Aug 2015 $0.1100 50.00% Final 14 Sep 2015
    18 Mar 2015 $0.0900 100.00% Interim 07 Apr 2015
    27 Aug 2014 $0.1100 100.00% Final 15 Sep 2014
    17 Mar 2014 $0.0900 100.00% Interim 07 Apr 2014
    16 Sep 2013 $0.1100 100.00% Final 08 Oct 2013
    18 Mar 2013 $0.0650 100.00% Interim 08 Apr 2013
    17 Sep 2012 $0.0600 100.00% Final 08 Oct 2012
    26 Mar 2012 $0.0500 100.00% Interim 16 Apr 2012
    19 Sep 2011 $0.0500 100.00% Final 10 Oct 2011
    21 Mar 2011 $0.0300 100.00% Interim 11 Apr 2011
    20 Sep 2010 $0.1000 100.00% Final 11 Oct 2010
    05 Mar 2010 $0.1500 100.00% Interim 29 Mar 2010
    07 Sep 2009 $0.0700 100.00% Final 28 Sep 2009
    16 Feb 2009 $0.0700 100.00% Interim 09 Mar 2009
    08 Sep 2008 $0.0500 100.00% Final 09 Oct 2008
    22 Feb 2008 $0.2200 100.00% Interim 17 Mar 2008
    31 Aug 2007 $0.2400 100.00% Final 24 Sep 2007
    09 Mar 2007 $0.2100 100.00% Interim 02 Apr 2007
    09 Oct 2006 $0.0800 100.00% Special Cash 30 Oct 2006
    04 Sep 2006 $0.2200 100.00% Final 25 Sep 2006
    20 Feb 2006 $0.2000 100.00% Interim 13 Mar 2006
    22 Aug 2005 $0.1300 100.00% Final 12 Sep 2005
    08 Apr 2004 $0.0750 100.00% Interim 03 May 2004

    HLS ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Healius Ltd

    Healius Ltd (ASX: HLS) operates a network of pathology laboratories, diagnostic imaging centres, and day hospitals across Australia.

    The company is Australia's second-largest pathology provider with around 2,000 collection sites and almost 100 pathology laboratories operating under a portfolio of brand names. The company says one in three pathology samples taken in Australia is tested in a Healius laboratory. It also operates around 150 imaging centres in public and private hospitals, medical centres, and community centres. 

    The company has identified its short-stay and day hospitals as a growth segment. It currently operates 15 day hospitals as well as four major IVF clinics. 

    HLS Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    27 Dec 2024 $1.40 $-0.02 -1.41% 497,837 $1.40 $1.43 $1.40
    24 Dec 2024 $1.42 $0.02 1.43% 235,401 $1.40 $1.42 $1.39
    23 Dec 2024 $1.40 $0.03 2.20% 657,588 $1.36 $1.40 $1.35
    20 Dec 2024 $1.37 $-0.03 -2.14% 1,225,782 $1.38 $1.40 $1.36
    19 Dec 2024 $1.40 $-0.03 -2.11% 2,018,691 $1.40 $1.41 $1.36
    18 Dec 2024 $1.43 $-0.01 -0.70% 1,694,542 $1.43 $1.45 $1.41
    17 Dec 2024 $1.44 $0.03 2.14% 787,950 $1.39 $1.46 $1.39
    16 Dec 2024 $1.41 $0.03 2.18% 1,697,900 $1.38 $1.41 $1.35
    13 Dec 2024 $1.38 $-0.01 -0.72% 1,047,294 $1.36 $1.40 $1.35
    12 Dec 2024 $1.39 $-0.02 -1.42% 1,531,266 $1.40 $1.41 $1.38
    11 Dec 2024 $1.41 $-0.04 -2.76% 580,883 $1.43 $1.45 $1.40
    10 Dec 2024 $1.45 $0.00 0.00% 2,293,795 $1.45 $1.47 $1.43
    09 Dec 2024 $1.45 $0.03 2.12% 1,126,245 $1.42 $1.45 $1.42
    06 Dec 2024 $1.42 $0.01 0.71% 757,437 $1.40 $1.44 $1.40
    05 Dec 2024 $1.41 $0.02 1.44% 1,065,402 $1.39 $1.42 $1.39
    04 Dec 2024 $1.39 $-0.02 -1.42% 1,093,215 $1.38 $1.41 $1.37
    03 Dec 2024 $1.41 $0.01 0.71% 1,316,503 $1.41 $1.43 $1.39
    02 Dec 2024 $1.40 $0.02 1.45% 744,903 $1.40 $1.42 $1.39
    29 Nov 2024 $1.38 $-0.02 -1.43% 1,012,859 $1.41 $1.41 $1.38

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    21 Nov 2024 Michael Stanford Buy 40,000 $53,200
    On-market trade.
    21 Nov 2024 Sally Evans Buy 30,418 $39,847
    On-market trade.
    20 Nov 2024 Paul Anderson Buy 37,837 $48,052
    On-market trade.
    20 Nov 2024 Kathryn (Kate) McKenzie Buy 40,000 $52,000
    On-market trade.
    27 Aug 2024 Sally Evans Buy 16,450 $25,000
    Conversion of securities. VWAP
    27 Aug 2024 Sally Evans Exercise 16,450 $25,000
    Conversion of securities. VWAP
    27 Aug 2024 Charlie Taylor Exercise 16,450 $25,000
    Conversion of securities. VWAP
    27 Aug 2024 Charlie Taylor Buy 16,450 $25,000
    Conversion of securities. VWAP
    21 May 2024 Kathryn (Kate) McKenzie Transfer 2,559 $3,224
    Off-market transfer.
    21 May 2024 Kathryn (Kate) McKenzie Transfer 2,559 $3,224
    Off-market transfer.
    14 May 2024 John Mattick Transfer 15,093 $20,224
    As advised by the company. a transfer of NED Restricted Shares to the custodian
    under the Healius NED Share Plan.
    14 May 2024 John Mattick Transfer 15,093 $20,224
    As advised by the company. Transfer of NED Restricted shares to the custodian under the
    Healius NED Share Plan
    14 May 2024 Gordon Davis Transfer 40,214 $53,886
    As advised by the company. Transfer of NED Restricted shares to the custodian
    under the Healius NED Share Plan.
    14 May 2024 Gordon Davis Transfer 40,214 $53,886
    As advised by the company. Transfer of NED Restricted shares to the custodian
    under the Healius NED Share Plan.
    14 May 2024 Sally Evans Transfer 51,332 $68,784
    As advised by the company. Transfer of NED Restricted shares to the custodian under the
    Healius NED Share Plan.
    14 May 2024 Sally Evans Transfer 51,332 $68,784
    As advised by the company. Transfer of NED Restricted shares to the custodian under the
    Healius NED Share Plan.
    14 May 2024 Charlie Taylor Transfer 16,450 $22,043
    As advised by the company. Transfer of NED Restricted shares to the custodian under the
    Healius NED Share Plan.
    14 May 2024 Charlie Taylor Transfer 16,450 $22,043
    As advised by the company. Transfer of NED Restricted shares to the custodian under the
    Healius NED Share Plan.
    15 Mar 2024 Charlie Taylor Buy 16,450 $25,000
    Conversion of securities.
    15 Mar 2024 Charlie Taylor Exercise 16,450 $25,000
    Conversion of securities. vwap, 16,450 NED Share Rights
    15 Mar 2024 Sally Evans Buy 16,450 $25,000
    Conversion of securities. vwap
    15 Mar 2024 Sally Evans Exercise 16,450 $25,000
    Conversion of securities. vwap, 16,450 NED Share Rights
    28 Feb 2024 Maxine Jaquet Issued 512,645 $1,499,999
    Issue of securities. vwap, 884,504 Performance Rights
    30 Jan 2024 Maxine Jaquet Expiry 1,667,805 $2,334,927
    Options expired.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Michael Philip Stanford Non-Executive Director Sep 2023
    Dr Stanford is a member of the People & Governance Committees. Michael has over 20 years of experience as a Chief Executive Officer and Managing Director of multi-campus and multi-service health care organisations with national and international areas of operation, including St John of God Health Care, Australian Hospital Care Ltd, North-Western Health, North-Eastern Health Care Network and Austin & Repatriation Medical Centre.
    Professor John Mattick Non-Executive Director Mar 2022
    Professor Mattick is a member of the Risk Management Committees. John is a Professor in the School of Biotechnology and Biomolecular Science at UNSW Sydney. He was Chief Executive of Genomics England and Executive Director of the Garvan Institute of Medical Research. He was a member of the Australian Health Ethics Committee of the National Health & Medical Research Council, an advisor to the Australian Law Reform Commission's Inquiry into the Protection of Human Genetic Information and Gene Patenting & Human Health.
    Mr Paul Anderson Chief Executive OfficerManaging Director Mar 2024
    Mr Anderson has background in industries facing disruption. He was previously Chief Executive Officer of Network Ten and more recently, Executive Vice President at Viacom CBS Networks Australia & NZ. He also spent more than a decade working abroad at CLS Holdings plc in London and KPMG in New Zealand.
    Ms Kathryn (Kate) Mary McKenzie Non-Executive Director Feb 2021
    Ms McKenzie is Chair of the Risk Committee and a member of the People & Governance Committee. Kate has corporate governance experience and has held several executive roles, including CEO of Chorus Limited (NZ) and COO of Telstra. She also held the roles of CEO of the NSW Department of Commerce and CEO of WorkCover. She is on the Board of Stockland and Chair of nbnco.
    Ms Sally Evans Non-Executive Director Aug 2018
    Ms Evans is Chair of the People & Governance Committee and a member of the Risk Management Committee. Sally has over 30 years of experience in private, government and social enterprise sectors and has worked in Australia, New Zealand, the United Kingdom, and Hong Kong with responsibilities across the broader Asia Pacific region. She is a board member of Allianz Australia Life, Oceania Healthcare (NZ) and Ingenia Communities.
    Ms Katherine (Kathy) Ostin Non-Executive Director Dec 2024
    Ms Ostin was an Audit, Assurance and Risk Consulting Partner at KPMG from 2005 to 2017 and has experience in the aged care and healthcare sectors, having established and led KPMGs Health, Aging and Human Services audit practice from 2006 to 2018. During her 24 years with KPMG, Ms Ostin worked in Australia, the US, Asia and UK. Ms Ostins other current ASX board and audit chair roles include for 3P Learning Limited (ASX:3PL) as a Non-Executive Director and Chair of Audit & Risk Committee, Capral Limited (ASX:CAP) as a Non Executive Director and Chair of Audit & Risk Committee, dusk Group Limited (ASX:DSK) as a Non Executive Director and Chair of Audit & Risk Committee, Elanor Investors Group (ASX:ENN) and Elanor Commercial Property Fund (ASX:ECF) as a Non-Executive Director and Next Science Limited (ASX:NXS) as a Non-Executive Director and Chair of Audit & Risk Committee.
    Mr Charlie Taylor Non-Executive Director Mar 2023
    Mr Taylor has over 30 years of experience in international advisory firms, including as Senior Partner at McKinsey where he led the Health and Public Sector practices. He has advised many of Australia's private and public sector healthcare organisations and initiated multi-year research efforts on healthcare, Covid response, productivity, and innovation. He is also a member of People & Governance Committee.
    Mrs Mary Weaver Company Secretary Mar 2023
    -
    Mr Stephen Humphries Company Secretary Mar 2023
    -
    Steve Humphries Chief Financial Officer
    -
    Mary Weaver Company Secretary
    -
    Stephen Humphries Company Secretary
    -
    Prasad Arav Group Executive Digital & Technology and Strategy
    -
    Phil Lucas Group Executive Lumus Imaging
    -
    Paula Bayliss Group Executive People & Culture
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 211,636,287 29.15%
    Citicorp Nominees Pty Limited 209,962,638 28.92%
    J P Morgan Nominees Australia Pty Limited 127,569,782 17.57%
    Argo Investments Limited 22,874,452 3.15%
    BNP Paribas Noms Pty Ltd 19,666,305 2.71%
    BNP Paribas Nominees Pty Ltd <Agency Lending A/C> 12,096,389 1.67%
    HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> 5,855,473 0.81%
    Citicorp Nominees Pty Limited <Colonial First State Inv A/C> 4,335,651 0.60%
    National Nominees Limited 3,718,898 0.51%
    First Samuel Ltd Acn 086243567 <Anf Its Mda Clients A/C> 3,469,215 0.48%
    Rinrim Pty Ltd 2,497,161 0.34%
    HSBC Custody Nominees (Australia) Limited i 2,037,242 0.28%
    BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> 939,397 0.12%
    HSBC Custody Nominees (Australia) Limited <Gsco Customers A/C> 838,693 0.12%
    Netwealth Investments Limited <Wrap Services A/C> 731,765 0.10%
    Joromada Pty Ltd 660,000 0.09%
    Buttonwood Nominees Pty Ltd 658,941 0.09%
    Sep Super Pty Ltd <Sep Super Fund A/C> 637,236 0.09%
    Mr Gregory Anthony Thomas Bateman 636,213 0.08%
    Ioof Investment Services Limited <Ips Superfund A/C> 609,635 0.08%

    Profile

    since

    Note